Congenital Heart Disease (CHD) Market Report 2025

This Congenital Heart Disease (CHD) market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The congenital heart disease (CHD) market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.

The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.

The growing prevalence of maternal diabetes is expected to drive the expansion of the congenital heart disease (CHD) market in the future. Maternal diabetes, also known as gestational diabetes mellitus (GDM), develops during pregnancy in women who did not have diabetes before conceiving. It is primarily caused by lifestyle changes, such as sedentary behavior, poor dietary habits, and rising obesity rates among women of childbearing age. Maternal diabetes can increase the risk of congenital heart disease (CHD) in infants, as elevated blood sugar levels in the mother can disrupt fetal heart development. The high glucose levels affect the normal formation of the baby's heart, leading to a higher likelihood of CHD. For example, in October 2023, the National Health Service, a UK government agency, reported that adverse pregnancy outcomes for women diagnosed with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. As a result, the rising number of maternal diabetes cases is contributing to the growth of the congenital heart disease (CHD) market.

Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient outcomes and quality of life. Non-surgical heart valves, also known as transcatheters, are medical devices treating heart valve diseases without conventional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system, a minimally invasive alternative to open-heart surgery, addresses patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve designed for the right side, offering a non-surgical solution for severe pulmonary valve regurgitation patients. The Harmony TPV System received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, underscoring Medtronic's dedication to advancing solutions for congenital heart disease patients.

In May 2024, Novartis Healthcare Private Limited, a Switzerland-based pharmaceutical company, partnered with Ayala Healthcare Holdings, Inc. (AC Health) to launch an Integrated Cardiovascular and Cancer Care initiative. This collaboration aims to expand access to innovative treatments for breast cancer, heart failure, and high cholesterol. Ayala Healthcare Holdings, Inc. (AC Health) is a Philippines-based pharmaceutical company specializing in generic drugs.

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd.

North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congenital heart disease (CHD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Congenital heart disease (CHD) encompasses a spectrum of birth defects affecting the structure and function of the heart present at birth. These defects may involve abnormalities in the heart walls, valves, arteries, and veins near the heart. Treatment for CHD varies depending on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

The primary types of congenital heart disease (CHD) include heart valve defects, heart wall defects, blood vessel defects, and others. Heart valve defects entail abnormalities or malfunctions in the heart valves, which regulate blood flow within the heart. Diagnosis methods may include electrocardiograms, chest X-rays, echocardiograms, transesophageal echocardiograms, pulse oximetry, exercise stress tests, cardiac computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, among others. Treatment options range from interventional cardiology procedures to cardiac surgery, medication management, telemedicine, and lifestyle modifications. CHD affects individuals across all age groups, including infants, children, adolescents, and adults, who receive treatment in hospitals, clinics, diagnostic centers, ambulatory surgical centers, and research and academic institutions.

The congenital heart disease market research report is one of a series of new reports that provides congenital heart disease market statistics, including congenital heart disease industry global market size, regional shares, competitors with a congenital heart disease market share, detailed congenital heart disease market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart disease industry. This congenital heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital heart disease (CHD) market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital heart disease (CHD) market also includes sales of cardiac implants such as pacemakers, implantable cardioverter-defibrillators (ICDs), and ventricular assist devices (VADs). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.